Lonza snaps up Cambrex 'bio businesses'

By Susan Gotensparre

- Last updated on GMT

Related tags Lonza Biotechnology

Contract manufacturer Lonza has completed its acquisition of two
Cambrex subsidiaries, research bioproducts and microbial
biopharmaceutical, in a move that is fuelled by its strategic move
into biopharmaceuticals.

The $460m (€354.2m) deal was announced in October 2006 but was not closed until 5 February, following the consent of Cambrex shareholders.

Lonza said its existing biopharmaceuticals business sector would integrate the microbial biopharmaceutical division's expertise within microbial fermentation, to support its growth.

In contrast, the research bioproducts division will be renamed as 'Lonza Bioscience' and will operate as a stand-alone business unit. The division has a leading position within endotoxin detection, cell-based research and cell therapy manufacturing, and is complementary to Lonza's biopharmaceuticals division.

"The closing of the Cambrex Bio-Businesses acquisitions marks an important milestone within Lonza's transformation into a focused life sciences company,"​ said Stefan Borgas, CEO of Lonza.

"Together we will build upon Lonza's track record to deliver outstanding products and services to support our customer's research and manufacturing processes, and extend our reach further with the addition of the new Bioproducts business. By joining forces globally, we strengthen Lonza's strategic position and our growth potential as a worldwide leader servicing our life sciences customers."

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more